Investigation of Serum Folate-Receptor-1 Levels in Patients with Non-Small Cell Lung Cancer
- 20 October 2022
- journal article
- research article
- Published by Konuralp Medical Journal in Konuralp Tip Dergisi
- Vol. 14 (3) , 526-532
Abstract
Objective: Histopathological overexpression of folate receptor-1 (FOLR1) involved in folate transport in cell growth has been reported in various cancers. Increased serum FOLR1(sFOLR1) has also been reported in epithelial ovarian cancer. The aim was to investigate sFOLR1 levels in non-small cell lung cancer (NSCLC) patients and the response prediction of the standard chemotherapy targeting folic acid metabolism. Method: In this prospective study, sFOLR1 levels were investigated in 30 healthy individuals and 60 patients with stage4 malign metastatic NSCLC before and after standard chemotherapy. The commercial immunoassay (ELISA) kit used for analysis of sFOLR1. Serum carcinoembryonic antigen (CEA), vitamin B12, and folate levels were also investigated. Result: In NSCLC patients sFOLR1 levels were significantly higher(p<0.001) than the healthy individuals. After 3 months of standard treatment, sFOLR1 was significantly lower in patients(p<0.001). Diagnostic accuracy was strong in the differentiation of NSCLC patients from healthy individuals (AUC= 0.966). with the cut-off point of 82.45 pg/ml, the sFOLR1 level was performed with 95% sensitivity and 99% specificity. Pretreatment sFOLR1 levels were significantly lower in patients with-response to standard chemotherapy(p<0.01). The best predictive value was determined as 393.80 pg/ml. At the end of the 401 days, a significant difference found in patients with high the sFOLR1 predictive value. The median overall survival (OS) duration was 288 days for all patients (95% GA 198.13-377.87). Median progression-free survival (PFS) was 321 days (95% GA 211.90-430.10). Conclusion: For monitoring standard chemotherapy with drugs targeting folic acid metabolism, sFOLR-1 levels may be important biomarker.Keywords
Funding Information
- YOK (2018.110.08.01)
This publication has 23 references indexed in Scilit:
- Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patientsClinical Biochemistry, 2013
- Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4Journal of Ovarian Research, 2013
- Folate Receptor in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: Potential Target for Folate-Linked Therapeutic AgentsArchives of Pathology & Laboratory Medicine, 2013
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and ElaborationPLOS Medicine, 2012
- High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and MutationJournal of Thoracic Oncology, 2012
- New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted TherapyAmerican Journal of Roentgenology, 2010
- Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer PatientsPLOS ONE, 2009
- Expression Status of Folate Receptor α Is Significantly Correlated with Prognosis in Non-Small-Cell Lung CancersAnnals of Surgical Oncology, 2008
- Folate receptor overexpression is associated with poor outcome in breast cancerInternational Journal of Cancer, 2007
- The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander?International Journal of Cancer, 2006